Skip to main content
The BMJ logoLink to The BMJ
. 1994 Apr 9;308(6934):961–966. doi: 10.1136/bmj.308.6934.961

Cancer of the head and neck.

J S Tobias 1
PMCID: PMC2539765  PMID: 8173406

Abstract

Cancers of the upper aerodigestive tract, collectively known as head and neck cancers, arise from a multiplicity of sites. In the West, excess tobacco and alcohol consumption are the most important of the known predisposing factors; elsewhere in the world, notably in India and China, the aetiology, pattern of primary sites, and clinical behaviour are different. Clinically these tumours pose exceptional problems in management, and skilled multidisciplinary teams are necessary in order to achieve the highest level of service and research. Historically, surgery and radiotherapy have been the most important treatment modalities; chemotherapy is now increasingly employed but not yet fully established. Successful rehabilitation of patients with head and neck cancers requires access to high quality speech therapists and other support staff with training in functional pharyngeal disorders. Current research efforts are largely directed towards defining the proper role of chemotherapy and assessing the possible advantage of unconventional radiation approaches. In recent years the roles of primary, reconstructive, and salvage surgery have also become better defined. Many patients are suitable for randomisation into ongoing prospective clinical trials which have been specifically designed to address these issues.

Full text

PDF
961

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ang K. K., Peters L. J., Weber R. S., Maor M. H., Morrison W. H., Wendt C. D., Brown B. W. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1339–1345. doi: 10.1016/0360-3016(90)90341-g. [DOI] [PubMed] [Google Scholar]
  2. Clavel M., Maged Mansour A. R. Head and neck cancer: prognostic factors for response to chemotherapy. Eur J Cancer. 1991;27(3):349–356. doi: 10.1016/0277-5379(91)90544-n. [DOI] [PubMed] [Google Scholar]
  3. Gupta N. K., Pointon R. C., Wilkinson P. M. A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol. 1987 Nov;38(6):575–581. doi: 10.1016/s0009-9260(87)80327-6. [DOI] [PubMed] [Google Scholar]
  4. Horiot J. C., Le Fur R., N'Guyen T., Chenal C., Schraub S., Alfonsi S., Gardani G., Van den Bogaert W., Danczak S., Bolla M. Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial. Eur J Cancer. 1990;26(7):779–780. doi: 10.1016/0277-5379(90)90150-r. [DOI] [PubMed] [Google Scholar]
  5. Hutchison I. Improving the poor prognosis of oral squamous cell carcinoma. BMJ. 1994 Mar 12;308(6930):669–670. doi: 10.1136/bmj.308.6930.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jacobs C. The internist in the management of head and neck cancer. Ann Intern Med. 1990 Nov 15;113(10):771–778. doi: 10.7326/0003-4819-113-10-771. [DOI] [PubMed] [Google Scholar]
  7. Leroy M., Teillac P., Rain J. D., Saccavini J. C., Le Duc A., Najean Y. Radioimmunodetection of lymph node invasion in prostatic cancer. The use of iodine 123 (123I)-labeled monoclonal anti-prostatic acid phosphatase (PAP) 227 A F(ab')2 antibody fragments in vivo. Cancer. 1989 Jul 1;64(1):1–5. doi: 10.1002/1097-0142(19890701)64:1<1::aid-cncr2820640102>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  8. Merlano M., Vitale V., Rosso R., Benasso M., Corvò R., Cavallari M., Sanguineti G., Bacigalupo A., Badellino F., Margarino G. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992 Oct 15;327(16):1115–1121. doi: 10.1056/NEJM199210153271602. [DOI] [PubMed] [Google Scholar]
  9. Møller H. Changing incidence of cancer of the tongue, oral cavity, and pharynx in Denmark. J Oral Pathol Med. 1989 Apr;18(4):224–229. doi: 10.1111/j.1600-0714.1989.tb00767.x. [DOI] [PubMed] [Google Scholar]
  10. Shanta V., Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. Clin Radiol. 1980 Sep;31(5):617–620. doi: 10.1016/s0009-9260(80)80069-9. [DOI] [PubMed] [Google Scholar]
  11. Stell P. M., Rawson N. S. Adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1990 May;61(5):779–787. doi: 10.1038/bjc.1990.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tobias J. S. Current role of chemotherapy in head and neck cancer. Drugs. 1992 Mar;43(3):333–345. doi: 10.2165/00003495-199243030-00004. [DOI] [PubMed] [Google Scholar]
  13. Tobias J. S. Has chemotherapy proved itself in head and neck cancer? Br J Cancer. 1990 May;61(5):649–651. doi: 10.1038/bjc.1990.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Vokes E. E., Weichselbaum R. R., Lippman S. M., Hong W. K. Head and neck cancer. N Engl J Med. 1993 Jan 21;328(3):184–194. doi: 10.1056/NEJM199301213280306. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES